Stock ANAB ANAPTYSBIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company AnaptysBio, Inc.

Equities

ANAB

US0327241065

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
23.95 USD +1.27% Intraday chart for AnaptysBio, Inc. +0.17% +11.81%
May. 09 AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 09 Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis CI

Business Summary

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Number of employees: 117

Sales per Business

USD in Million2022Weight2023Weight Delta
GSK - Royalty
100.0 %
5 51.4 % 17 100.0 % +224.51%

Sales per region

USD in Million2022Weight2023Weight Delta
United States and Australia
100.0 %
10 100.0 % 17 100.0 % +66.78%

Managers

Managers TitleAgeSince
Daniel Faga CEO
 Chief Executive Officer 44 21-11-25
Dennis Mulroy DFI
 Director of Finance/CFO 69 20-07-14
Paul Lizzul CTO
 Chief Tech/Sci/R&D Officer 49 20-07-30
Nick Montemarano IRC
 Investor Relations Contact - -
Priya Raina PRN
 Corporate Officer/Principal - 22-06-30
Ben Stone PRN
 Corporate Officer/Principal - 21-12-31
Martin Dahl PRN
 Corporate Officer/Principal - 17-12-31
Beth Mueller HRO
 Human Resources Officer - 19-09-30
David McKeon AUD
 Comptroller/Controller/Auditor 52 17-03-31
Lewis Gryziewicz LAW
 General Counsel - 18-12-31

Members of the board

Members of the board TitleAgeSince
Hollings Renton BRD
 Director/Board Member 77 15-06-29
Dennis Fenton BRD
 Director/Board Member 72 18-03-04
Magda Marquet BRD
 Director/Board Member 65 21-01-17
Oleg Nodelman BRD
 Director/Board Member 47 21-04-07
John Schmid BRD
 Director/Board Member 61 15-06-29
John Orwin CHM
 Chairman 59 23-09-14
J. Ware BRD
 Director/Board Member 71 17-08-23
Daniel Faga CEO
 Chief Executive Officer 44 21-11-25
Rita Jain BRD
 Director/Board Member 62 23-04-05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 27,318,644 26,799,162 ( 98.10 %) 0 98.10 %

Shareholders

NameEquities%Valuation
EcoR1 Capital, LLC
28.10 %
7,521,024 28.10 % 142 M $
BlackRock Advisors LLC
5.858 %
1,567,694 5.858 % 30 M $
Vanguard Fiduciary Trust Co.
5.059 %
1,354,003 5.059 % 26 M $
Tang Capital Management LLC
4.973 %
1,330,879 4.973 % 25 M $
Boxer Capital LLC
4.857 %
1,300,000 4.857 % 25 M $
STATE STREET CORPORATION
4.511 %
1,207,404 4.511 % 23 M $
Jeffrey Robert Jay
3.650 %
976,981 3.650 % 18 M $
First Light Asset Management LLC
3.528 %
944,110 3.528 % 18 M $
Frazier Life Sciences Management LP
3.362 %
899,700 3.362 % 17 M $
Point72 Asset Management LP
3.229 %
864,100 3.229 % 16 M $

Company contact information

AnaptysBio, Inc.

10770 Wateridge Circle Suite 210

92121-5801, San Diego

+858 362 6295

http://www.anaptysbio.com
address AnaptysBio, Inc.(ANAB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Ratings for AnaptysBio, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
23.94 USD
Average target price
43.78 USD
Spread / Average Target
+82.86%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ANAPTYSBIO, INC. Stock AnaptysBio, Inc.
+11.81% 654M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ANAB Stock
  4. Company AnaptysBio, Inc.